Guerrieri-Gonzaga A

ORCID: 0000-0003-1915-1688 · 1 paper in corpus
2013
A randomized phase II presurgical trial of weekly low-dose tamoxifen versus raloxifene versus placebo in premenopausal women with estrogen receptor-positive breast cancer.
Breast cancer research : BCR ·doi:10.1186/bcr3439

IntroductionWe previously demonstrated that 1 or 5 mg per day of tamoxifen (T) given for four weeks before surgery reduces Ki-67 in breast cancer (BC) patients to the same extent as the standard 20 mg/d. Given the long half-life of T, a wee…